| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 01/14/2004 | EP1379248A1 Tricyclic compounds useful as hiv reverse transcriptase inhibitors |
| 01/14/2004 | EP1379246A1 Nociceptin analogs |
| 01/14/2004 | EP1379243A1 Methods for treating metabolic diseases using malonyl-coa decarboxylase inhibitors |
| 01/14/2004 | EP1379242A1 Method for treatment of cancer and compositions for use therein |
| 01/14/2004 | EP1379241A1 Compounds and methods |
| 01/14/2004 | EP1379240A1 Compounds and methods |
| 01/14/2004 | EP1379238A1 Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer |
| 01/14/2004 | EP1379235A2 Compositions and methods for enhancing paracellular permeability across epithelial and endothelial barriers |
| 01/14/2004 | EP1379232A2 N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity |
| 01/14/2004 | EP1379225A2 Novel medicament compositions based on anticholinergic agents and endothelin antagonists |
| 01/14/2004 | EP1379224A1 Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
| 01/14/2004 | EP1379140A2 Production of pancreatic islet cells and delivery of insulin |
| 01/14/2004 | EP1379130A2 Composition and method for preventing and treating sinusoidal obstruction syndrome and radiation-induced liver disease |
| 01/14/2004 | EP1341535A4 Skin whiteners containing hydroxytetronic acid |
| 01/14/2004 | EP1272189A4 Inhibition of cyclooxygenase-2 activity |
| 01/14/2004 | EP1116725B1 Process for obtaining 17beta-(n-terc-butylcarbamoyl)-3-one-4-aza-steroids |
| 01/14/2004 | EP1115404B1 Use of prostanoid antagonists for the treatment of primary headache disorders |
| 01/14/2004 | EP1095018B1 Aminoiminoquinone and aminoquinone alkaloid compounds as caspase inhibitors |
| 01/14/2004 | EP1082117B1 A stabilized antihistamine syrup containing aminopolycarboxylic acid as stabilizer |
| 01/14/2004 | EP1056448B1 Pharmaceutical combinations containing tramadol |
| 01/14/2004 | EP1019385B1 Aminoaryl oxazolidinone n-oxides |
| 01/14/2004 | EP1019059A4 USE OF FXR, PPARalpha AND LXRalpha ACTIVATORS TO RESTORE BARRIER FUNCTION, PROMOTE EPIDERMAL DIFFERENTIATION AND INHIBIT PROLIFERATION |
| 01/14/2004 | EP1014989B1 Endothelin antagonist and a renin-angiotensin system inhibitor as a combined preparation |
| 01/14/2004 | EP1014965B1 Dietary compositions for enhancing metabolism and alleviating oxidative stress |
| 01/14/2004 | EP0939644B1 Enhanced stimulation of erythropoiesis |
| 01/14/2004 | EP0934074B1 Use of ginkgo biloba flavonoidic extract comprising up to 1% of terpenes, associated with ceramides, for oral hygiene and compositions containing such extract |
| 01/14/2004 | EP0832091B1 C-4' modified adenosine kinase inhibitors |
| 01/14/2004 | CN1468309A Anti-il-12 antibodies, compositions, methods and uses |
| 01/14/2004 | CN1468308A Anti-tnf antibodies, compositions, methods and uses |
| 01/14/2004 | CN1468307A Anti-dual integrin antibodies, compositions, methods and uses |
| 01/14/2004 | CN1468302A Gsk3 polypeptides |
| 01/14/2004 | CN1468258A Glucagon-like peptide-1 analogs |
| 01/14/2004 | CN1468257A Trichosanthin mutant |
| 01/14/2004 | CN1468253A 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents |
| 01/14/2004 | CN1468252A 6.alpha., 9.alpha.-difluoro-17.alpha.-[(2-furanylcarboxyl) oxy]-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent |
| 01/14/2004 | CN1468249A Methods and compositions for treating flaviviruses and pestiviruses |
| 01/14/2004 | CN1468241A Heterocyclic compounds as ligands of the gabaa receptor |
| 01/14/2004 | CN1468239A Substituted pyrazoles |
| 01/14/2004 | CN1468236A Novel anticholinergic agents that can be used as medicaments and method for the production thereof |
| 01/14/2004 | CN1468234A Perfluoroalkyl-containing complexes with sugar radicals, process for their production and their use |
| 01/14/2004 | CN1468233A Novel aminotriazolone compounds, method for preparing same and pharmaceutical compositions containing same |
| 01/14/2004 | CN1468232A Heterocyclic sodium/proton exchange inhibitors and method |
| 01/14/2004 | CN1468230A Chemical compounds |
| 01/14/2004 | CN1468228A 7-carboxy-flavone derivatives, preparation method and therapeutic use |
| 01/14/2004 | CN1468227A Non-imidazole aryloxyalkylamines |
| 01/14/2004 | CN1468226A Biphenyl derivatives and their use as ppar-gamma receptor activators |
| 01/14/2004 | CN1468225A 4-pyrimidinamine derivatives, pharmaceutical compositions and related methods |
| 01/14/2004 | CN1468224A Derivatives of quinoline as alpha-2 antagonists |
| 01/14/2004 | CN1468221A Non-imidazole aryloxypiperidines |
| 01/14/2004 | CN1468220A New piperidine derivatives |
| 01/14/2004 | CN1468219A Piperidine derivatives and drugs containing these derivatives as the active ingredient |
| 01/14/2004 | CN1468217A Aliphatic nitrogenous five-membered ring compounds |
| 01/14/2004 | CN1468216A Nitrogenous five-membered ring compounds |
| 01/14/2004 | CN1468207A New retinoids for the treatment of emphysema |
| 01/14/2004 | CN1468112A The use of 5ht4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions |
| 01/14/2004 | CN1468111A A pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines |
| 01/14/2004 | CN1468106A Sugar absorption inhibitors and process for producing the same |
| 01/14/2004 | CN1468104A Use, in combination, of a purine activity and a nonsteroidal anti-inflammatory drug for preparing an anti-thrombotic and/or anti-inflammatory drug |
| 01/14/2004 | CN1468102A Modified prodrug forms of ap/amp |
| 01/14/2004 | CN1468100A Pharmaceutical compositions and methods for use |
| 01/14/2004 | CN1468098A Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same |
| 01/14/2004 | CN1468094A New pharmaceutical compositions containing epinastine and pseudoephedrine |
| 01/14/2004 | CN1468086A Melanogenesis inhibitors and whitening agents comprising ergosterol derivative and compositions containing ergosterol derivative |
| 01/14/2004 | CN1468060A Oil/fat composition |
| 01/14/2004 | CN1466995A Anti-consenescence capsule containing modification SOD |
| 01/14/2004 | CN1466991A Antimutagenic effects of ganoderma lucidum spores |
| 01/14/2004 | CN1466958A Anti-consenescence anti-fatigue health-product containing pure plant extracts |
| 01/14/2004 | CN1466957A Reinforced functional anti-fatigue health-product containing pure plant extracts |
| 01/14/2004 | CN1466939A Cosmetic and/or dermatological use of a composition containing at least one oxidation-sensitive hydrophilic active stabilised by at least one polymer or copolymer of maleic anhydride |
| 01/14/2004 | CN1134452C Novel vitamin D receptor related polypeptides, nucleic acid sequence encoding the same and uses thereof |
| 01/14/2004 | CN1134442C Pyrazolopyrimidinone cGMPPDE 5 inhibitors, method for preparing the same and uses and intermediate |
| 01/14/2004 | CN1134439C Pyrrolo [2,3D] pyrimidines and their use as tyrosine kinase inhibitors |
| 01/14/2004 | CN1134438C Bicyclic heteroaromatic compounds, method for prepearing the same and uses |
| 01/14/2004 | CN1134433C Novel aminooxyamide tricyclic inhibitors of farnesylprotein transferase |
| 01/14/2004 | CN1134430C Crystal modification of N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
| 01/14/2004 | CN1134423C Adhesion receptor antagonists |
| 01/14/2004 | CN1134420C Novel substituted imidazole compounds |
| 01/14/2004 | CN1134415C Process for making diaryl pyridines useful as cox-2 inhibitors |
| 01/14/2004 | CN1134414C Substituted oximes, hydrazones and olefins as neurokinin antagonists |
| 01/14/2004 | CN1134413C Sulfonyl pyrrolidone containing compound and its preparation and pharmaceutical application |
| 01/14/2004 | CN1134412C N-substituted 2-cyanopyrodlidines |
| 01/13/2004 | US6677450 N12, n13-bridged sugar derivatives of indolylopyrrolocarbazoles, useful in inhibiting the proliferation of tumor cells |
| 01/13/2004 | US6677432 Osteogenic protein-1 mutant having at least one amino acid residue substitution, and having improved in vitro refolding properties in ph range of about 6.0-9.0 |
| 01/13/2004 | US6677383 Hydroxylation activated prodrugs |
| 01/13/2004 | US6677376 Complexes comprising rotamase inhibitors and cyclophilins, administered for prevention of neurodegenarative diseases such as parkinson's or alzheimer's disease |
| 01/13/2004 | US6677374 Nervous system disorders |
| 01/13/2004 | US6677373 Polymorphic B form of 3-(cyclopropylmethoxy)-4-[4-(methylsulfonyl)phenyl]-5,5-dimethyl-5H-furan-2-one |
| 01/13/2004 | US6677370 Stabilizing microtubules and preventing depolymerization; antiproliferative, anticarcinogenic and antiinflammatory agents; autoimmune diseases |
| 01/13/2004 | US6677368 4-aryl substituted indolinones |
| 01/13/2004 | US6677367 Lysine derivative with 2-aminosulfonylthiophene substituent; acquired immunodeficiency syndrome (aids) viricides |
| 01/13/2004 | US6677366 Methods, compositions and articles for reducing or preventing the effects of inflammation |
| 01/13/2004 | US6677365 Antagonists of MCP-1 function and methods of use thereof |
| 01/13/2004 | US6677361 Topical formulations for the transdermal delivery of niacin and methods of treating hyperlipidemia |
| 01/13/2004 | US6677358 NIDDM regimen |
| 01/13/2004 | US6677356 Concurrently administering pyridoxal-5'-phosphate, pyridoxamine, pyridoxal, or a 3-acylated pyridoxal analogue with angiotensin converting enzyme inhibitor,calcium channel blocker, adrenergic blocking agent, vasodilator or diuretic |
| 01/13/2004 | US6677355 Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors |
| 01/13/2004 | US6677354 Treating sleep, brain, sexual, cardiovascular, nervous system, psychological, glandular, and gastrointestinal disorders |
| 01/13/2004 | US6677352 Non-insulin dependent, latent autoimmune, gestational diabetes treatment; impaired glucose tolerance; obesity, hypotensive agents |
| 01/13/2004 | US6677351 Useful in treatment of asthma and inflammation |
| 01/13/2004 | US6677344 Chymase inhibitor for the treatment of eosinophilia |